2025年11月12日关闭的 " Pharmacorp Rx公司 " 推出了1 500万加元的股票,以促进收购和扩张。 PharmaCorp Rx Inc. launched a C$15M stock offering to boost acquisitions and expansion, closing Nov. 12, 2025.

Pharmacorp Rx公司发起了1 500万科多巴元的公开买卖,Canaccord Genuity和Acenial Capital同意购买3 570万套,每套0.42科多巴元。 PharmaCorp Rx Inc. has launched a C$15 million bought deal public offering, with Canaccord Genuity and Acumen Capital agreeing to purchase 35.7 million units at C$0.42 each. 每个单位包括一股和一半的证券,可在24个月内以C$0.50行使. Each unit includes one share and half a warrant, exercisable at C$0.50 within 24 months. 收益将为购置和周转资金提供资金。 Proceeds will fund acquisitions and working capital. 预计将于2025年11月12日关闭,等待批准。 Closing is expected Nov. 12, 2025, pending approvals. 魁北克或美国没有提供这种药品,这是通过收购和重新命名扩大其药店网络的更广泛战略的一部分。 The offering is not available in Quebec or the U.S. and is part of a broader strategy to expand its pharmacy network through acquisitions and rebranding. 根据PCRX进行TSX风险交易所的股票交易。 Shares trade on the TSX Venture Exchange under PCRX.